Loading...
Publication
Gestão da síndrome do intestino irritável na farmácia comunitária
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 4.01 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
A Síndrome do Intestino Irritável (SII) é uma doença gastrointestinal crónica que afeta entre 5 % e 20 % da população mundial, com uma prevalência que varia consoante as regiões e os critérios de diagnóstico (Camilleri et al., 2021), (Chey et al., 2020). Caracterizada por dores abdominais e alterações do trânsito intestinal, a SII tem um impacto significativo na qualidade de vida dos pacientes e gera elevados custos socioeconómicos, devido às consultas médicas, à medicação e a uma produtividade reduzida (Ford et al., 2019). O tratamento desta doença permanece complexo devido à diversidade dos sintomas e das causas subjacentes, que incluem fatores genéticos, ambientais, psicológicos e alterações da microbiota intestinal (Norlin et al., 2021). Assim, é necessária uma intervenção integrada e personalizada para responder às necessidades dos pacientes com SII, especialmente no contexto da farmácia comunitária, onde o farmacêutico desempenha um papel central no acompanhamento e na educação dos pacientes. Esta monografia tem com objetivo: Revisão teórica da SII e desenvolvimento de um guia de intervenção para farmacêuticos comunitários. Neste contexto, esta monografia destacará: (i) uma compreensão aprofundada e abrangente da fisiopatologia da Síndrome do Intestino Irritável; (ii) as abordagens terapêuticas e as intervenções possíveis para a gestão da SII; e (iii) intervenção farmacêutica no acompanhamento dos pacientes com SII.
Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disease that affects between 5% and 20% of the global population, with a prevalence that varies depending on the regions and diagnostic criteria (Camilleri et al., 2021 ; Chey et al., 2020). Characterized by abdominal pain and changes in bowel movements, IBS has a significant impact on patients' quality of life and generates high socioeconomic costs due to medical consultations, medication, and reduced productivity (Ford et al., 2019). The treatment of this disease remains complex due to the diversity of symptoms and underlying causes, which include genetic, environmental, and psychological factors, as well as alterations in the gut microbiota (Norlin et al., 2021). Thus, an integrated and personalized intervention is necessary to meet the needs of patients with IBS, especially in the context of community pharmacy, where the pharmacist plays a central role in patient monitoring and education. This monograph aims to : conduct a theoretical review of IBS and develop an intervention guide for community pharmacists. In this context, this monograph will highlight : (i) a thorough and comprehensive understanding of the pathophysiology of Irritable Bowel Syndrome ; (ii) therapeutic approaches and possible interventions for managing IBS; and (iii) pharmaceutical intervention in the monitoring of patients with IBS.
Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disease that affects between 5% and 20% of the global population, with a prevalence that varies depending on the regions and diagnostic criteria (Camilleri et al., 2021 ; Chey et al., 2020). Characterized by abdominal pain and changes in bowel movements, IBS has a significant impact on patients' quality of life and generates high socioeconomic costs due to medical consultations, medication, and reduced productivity (Ford et al., 2019). The treatment of this disease remains complex due to the diversity of symptoms and underlying causes, which include genetic, environmental, and psychological factors, as well as alterations in the gut microbiota (Norlin et al., 2021). Thus, an integrated and personalized intervention is necessary to meet the needs of patients with IBS, especially in the context of community pharmacy, where the pharmacist plays a central role in patient monitoring and education. This monograph aims to : conduct a theoretical review of IBS and develop an intervention guide for community pharmacists. In this context, this monograph will highlight : (i) a thorough and comprehensive understanding of the pathophysiology of Irritable Bowel Syndrome ; (ii) therapeutic approaches and possible interventions for managing IBS; and (iii) pharmaceutical intervention in the monitoring of patients with IBS.
Description
Dissertação para obtenção do grau de Mestre no Instituto Universitário Egas Moniz
Keywords
Síndrome do intestino irritável (SII) Intervenção farmacêutica Fisiopatologia Farmácia comunitária